CLINICAL TRIALS PROFILE FOR CLIMARA
✉ Email this page to a colleague
505(b)(2) Clinical Trials for Climara
Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|---|
New Formulation | NCT00649896 ↗ | Evaluation of Adhesion Quality of a New Formulation of the Mylan Estradiol Transdermal System 0.025 mg/Day and Climara® Transdermal System 0.025 mg/Day | Completed | Mylan Pharmaceuticals | Phase 1 | 2003-08-01 | The primary objective of this study was to compare the adhesive quality of a new formulation of the Mylan Estradiol Transdermal System with that of Climara® Transdermal System following a single system application in 80 healthy postmenopausal female volunteers. As a secondary objective, primary dermal irritation was assessed after removal of each transdermal system. |
>Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Climara
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00154180 ↗ | Kronos Early Estrogen Prevention Study (KEEPS) | Unknown status | Albert Einstein College of Medicine | Phase 4 | 2005-09-01 | The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition. |
NCT00154180 ↗ | Kronos Early Estrogen Prevention Study (KEEPS) | Unknown status | Albert Einstein College of Medicine of Yeshiva University | Phase 4 | 2005-09-01 | The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition. |
NCT00154180 ↗ | Kronos Early Estrogen Prevention Study (KEEPS) | Unknown status | Brigham and Women's Hospital | Phase 4 | 2005-09-01 | The study will examine the effects of estrogen and progesterone on the development of atherosclerosis in menopausal women when hormone treatment is initiated within 3 years of the menopausal transition. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Climara
Condition Name
Clinical Trial Locations for Climara
Trials by Country
Clinical Trial Progress for Climara
Clinical Trial Phase
Clinical Trial Sponsors for Climara
Sponsor Name